Treatment of Patients With Node-Positive, HR-Positive/HER2-Negative Early Breast Cancer at High Risk of Recurrence: monarchE 7-Year Outcomes
In his expert commentary, Seth Wander, MD, PhD, provides a comprehensive review of the latest data on the cyclin-dependent kinase (CDK)4/6 inhibitor abemaciclib for treating of high-risk, node-positive, hormone receptor–positive/HER2-negative early breast cancer.
